10:51 AM EDT, 07/17/2024 (MT Newswires) -- Atara Biotherapeutics ( ATRA ) said Wednesday the US Food and Drug Administration has accepted and granted priority review to the company's biologics license application for tabelecleucel, or tab-cel, with a target action date of Jan. 15, 2025.

With FDA's acceptance of the biologics license application, Atara said it is set to receive a $20 million milestone payment from Pierre Fabre Laboratories under the companies' expanded global partnership.

Tab-cel is a potential treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease in patients two years and older with at least one prior treatment, Atara said.

There are currently no treatments approved by the FDA for this setting, according to the company.

Atara shares were up 2.4% in recent trading.

Price: 12.57, Change: +0.30, Percent Change: +2.44